InvestorsHub Logo
Followers 14
Posts 489
Boards Moderated 0
Alias Born 11/22/2011

Re: Tadaaa post# 29225

Monday, 10/27/2014 7:36:59 PM

Monday, October 27, 2014 7:36:59 PM

Post# of 42929
The most likely scenario is that Celprogen will continue to be a subcontractor to MNZO and if MNZO is successful in getting a product to market, that's based on the patent, Sharma will receive a royalty.

The only important question is: how can a company with a sub $400,000 M/C raise the millions required to take a product to market?